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Summary
Background Malignant pleural mesothelioma incidence continues to rise, with few available evidence-based 
therapeutic options. Results of previous non-randomised studies suggested that video-assisted thoracoscopic partial 
pleurectomy (VAT-PP) might improve symptom control and survival. We aimed to compare efficacy in terms of overall 
survival, and cost, of VAT-PP and talc pleurodesis in patients with malignant pleural mesothelioma.
Methods We undertook an open-label, parallel-group, randomised, controlled trial in patients aged older than 18 years 
with any subtype of confirmed or suspected mesothelioma with pleural effusion, recruited from 12 hospitals in the UK. 
Eligible patients were randomly assigned (1:1) to either VAT-PP or talc pleurodesis by computer-generated random 
numbers, stratified by European Organisation for Research and Treatment of Cancer risk category (high vs low). The 
primary outcome was overall survival at 1 year, analysed by intention to treat (all patients randomly assigned to a treatment 
group with a final diagnosis of mesothelioma). This trial is registered with ClinicalTrials.gov, number NCT00821860.
Findings Between Oct 24, 2003, and Jan 24, 2012, we randomly assigned 196 patients, of whom 175 (88 assigned to talc 
pleurodesis, 87 assigned to VAT-PP) had confirmed mesothelioma. Overall survival at 1 year was 52% (95% CI 41–62) 
in the VAT-PP group and 57% (46–66) in the talc pleurodesis group (hazard ratio 1·04 [95% CI 0·76–1·42]; p=0·81). 
Surgical complications were significantly more common after VAT-PP than after talc pleurodesis, occurring in 
24 (31%) of 78 patients who completed VAT-PP versus ten (14%) of 73 patients who completed talc pleurodesis 
(p=0·019), as were respiratory complications (19 [24%] vs 11 [15%]; p=0·22) and air-leak beyond 10 days (five [6%] vs 
one [1%]; p=0·21), although not significantly so. Median hospital stay was longer at 7 days (IQR 5–11) in patients who 
received VAT-PP compared with 3 days (2–5) for those who received talc pleurodesis (p<0·0001).
Interpretation VAT-PP is not recommended to improve overall survival in patients with pleural effusion due to 
malignant pleural mesothelioma, and talc pleurodesis might be preferable considering the fewer complications and 
shorter hospital stay associated with this treatment. 
Funding BUPA Foundation.
Introduction
The incidence of malignant pleural mesothelioma 
continues to rise;1–3 however, few evidence-based 
therapeutic options are available. Cisplatin plus 
pemetrexed chemotherapy has been shown to confer a 
slight survival advantage.4,5 The role of surgical resection 
is uncertain, but several operative approaches have been 
described.6 Extrapleural pneumonectomy (EPP) has 
been assessed in several studies—most recently in the 
MARS trial7 as part of trimodality therapy. Lung-sparing 
approaches, including (extended) pleurectomy with 
decortication8–10 and video-assisted thoracoscopic partial 
pleurectomy (VAT-PP), have also been assessed,11,12 and 
might be particularly appropriate for patients with more 
advanced disease or comorbidities.
VAT-PP involves thoracoscopic debulking of the 
parietal pleura and visceral pleurectomy with 
decortication to release trapped lung.6 Results of non-
randomised studies examining VAT-PP suggest that 
VAT-PP improved symptom control compared with EEP11 
and possibly increased survival compared with biopsy 
alone.12 The standard approach to control pleural effusion 
in patients with malignant pleural mesothelioma is talc 
pleurodesis, either via a chest tube or, more recently, by 
thoracoscopy.
The MesoVATS trial was designed to establish whether 
VAT-PP improves survival in patients with pleural 
effusion secondary to malignant pleural mesothelioma 
when compared with talc pleurodesis, to provide a full 
economic analysis of these treatments, and to compare 
symptom control and quality-of-life outcomes.
Methods
Study design and participants  
MesoVATS was an open-label, parallel-group, 
multicentre, randomised, controlled trial that recruited 
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patients from 12 secondary or tertiary care hospitals in 
the UK. Eligible patients were those aged older than 
18 years with confirmed (any subtype) or suspected 
(working diagnosis) malignant pleural mesothelioma 
who had a pleural effusion. Participants had to be fit 
enough to undergo VAT-PP and provide informed 
consent. Exclusion criteria were previous attempted 
pleurodesis and previous primary treatment for 
mesothelioma. Patients with previous malignancy were 
eligible if they were no longer receiving anticancer 
treatment and had a confirmed diagnosis of malignant 
pleural mesothelioma. Those with a history of 
malignancy but with only suspected mesothelioma were 
excluded because the relation of the pleural disease and 
effusion to the original cancer would have been 
uncertain. Patients with suspected malignant pleural 
mesothelioma who were found to have non-malignant 
disease or non-mesothelioma malignancy after 
randomisation were excluded.
The trial was coordinated by Papworth Hospital 
Clinical Trials Unit (Cambridge, UK) and approved by 
Huntingdon Research Ethics Committee. After sterile 
talc was re-designated as a medicinal product in April, 
2011, the trial was registered with the Medicines and 
Healthcare Products Regulatory Agency (MHRA) in 
2011.
Randomisation
Patients were recruited by a local principal investigator 
and were randomised in a 1:1 ratio to either VAT-PP or 
talc pleurodesis by a computerised random-number 
generator in blocks of ten (appendix) via a telephone 
randomisation line at Papworth Hospital, operated by 
staff who were independent of the study. Randomisation 
was stratified according to risk (high vs low) using the 
European Organisation for Research and Treatment of 
Cancer (EORTC) prognostic score.13 Patients were 
defined as high risk if they met three or more of the 
following criteria: white blood cell count of greater than 
8·3 × 10⁹/L; non-epithelioid tumour type (or unknown 
cell type at randomisation); male sex; or Eastern 
Cooperative Oncology Group (ECOG) performance 
status of 1 or higher. The trial was open label, with 
patients, clinicians, and researchers all aware of the 
treatment allocation. The trial database was held at 
Papworth Hospital NHS Foundation Trust.
Procedures  
A detailed overview of the VAT-PP and talc pleurodesis 
techniques is described in the appendix. To ensure 
uniformity of approach, all surgeons discussed the 
VAT-PP procedure, and from Jan 13, 2009, they also 
recorded tumour extent and lung re-expansion before 
and after pleurectomy (appendix). At study outset, talc 
pleurodesis was done using talc slurry via an intercostal 
chest drain. From November, 2008, the protocol changed 
to allow talc pleurodesis by thoracoscopic poudrage.
Patients with confirmed mesothelioma at time of 
randomisation underwent either VAT-PP or talc 
pleurodesis (appendix). For patients with suspected 
(working diagnosis) mesothelioma randomly assigned to 
VAT-PP, two approaches were permitted: either diagnosis 
was confirmed by thoracoscopy before VAT-PP or VAT-PP 
was done directly. In the talc pleurodesis group, diagnosis 
could either be confirmed by thoracoscopic biopsy 
followed by subsequent talc instillation, or thoracoscopy 
with biopsy and talc poudrage were done as a single 
procedure (appendix).
Staging was determined by two radiologists 
independently using the International Mesothelioma 
Interest Group (IMIG) tumour stage and was based on 
the CT done before randomisation.14 Differences were 
resolved by consensus.
Adverse events were documented and assessed by the 
local investigator for seriousness, severity, and causality, 
and were recorded on the case report forms at each 
follow-up visit.
After completion of the study treatment, ongoing 
management was at the discretion of the managing 
clinician. No restrictions were placed on the subsequent 
use of chemotherapy, radiotherapy, or other palliative 
control measures.
For the economic analysis, all data on resource use was 
patient-level and obtained at baseline and at 1, 3, 6, and 
12 months on a bespoke data collection form (available 
on request). We multiplied resource use by costs and 
prices obtained from national sources (appendix). At 
baseline, data for type of procedure, days on a ward, days 
in intensive care, and complications were obtained by 
research nurses using information from hospital records. 
Follow-up information on hospital bed use, use of 
primary care services (eg, family doctor, practice nurse), 
radiotherapy, chemotherapy, hospice care, and diagnostic 
tests was obtained by researchers during patient 
interviews at 1, 3, 6, and 12 months. Some aspects were 
confirmed by hospital records—eg, dates of radiotherapy 
and number of chest radiographs. Information about 
consultations in primary care was patient-reported.
Outcomes  
The primary outcome was overall survival at 1 year after 
randomisation. At the end of the study, survival status for 
all patients was confirmed using the UK Office for 
National Statistics mortality register. Survival times were 
censored on June 17, 2013. Secondary outcomes were: 
presence or absence of apparent pleural effusion as 
assessed by the reporting radiologist on chest radiograph; 
quality of life measured using the EuroQol EQ-5D,15 
EORTC QLQ-C30 general cancer, and EORTC QLQ-LC13 
lung cancer questionnaires;16 lung function and exercise 
tolerance measured using spirometry and the shuttle 
walk test, respectively; complications; and cost to the 
health service measured by resource use retrieved from 
patient interviews and hospital records. For patients who 
See Online for appendix
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received their allocated treatment, each measure was 
assessed at randomisation (baseline) and 1, 3, 6, and 
12 months after treatment. For patients who did not 
undergo their allocated treatment, follow-up visits 
occurred at 1, 3, 6, and 12 months after randomisation. 
Because of operational reasons, the shuttle walk test was 
only available at five of the 12 centres, and therefore was 
only undertaken by a subset of patients.
Statistical analysis
On the basis of previous scientific literature17 and a local 
audit,12 we estimated 1-year overall survival to be 37% 
with talc pleurodesis and 59% with VAT-PP. To show this 
difference we needed 90 patients per group (5% two-sided 
significance) to give 80% power. Allowing for post-
randomisation exclusions, we planned to randomly 
assign 196 patients.
We analysed the primary endpoint in the intention-to-
treat population of patients with malignant pleural 
mesothelioma. We estimated 1-year overall survival with 
the Kaplan-Meier method, stratified for risk status, and 
compared differences between groups with a log-rank 
test. We used Cox proportional hazards models, stratified 
for risk group, to estimate relative risk of death in the 
12 months after randomisation. We compared length of 
hospital stay using the Wilcoxon rank sum test, and 
complication rates, including persistent pleural effusion 
rate, with Pearson’s χ² test. Because of the attrition rate 
in our study sample (due to death), the number of 
patients available for secondary outcomes decreased 
during follow-up. Therefore, we compared all repeated 
measures at each timepoint separately. We assessed 
overall survival, EQ-5D score, and quality-adjusted 
survival in high-risk and low-risk subgroups separately 
in the only preplanned subgroup analysis.
Initially, we analysed secondary outcomes separately at 
each timepoint in only patients who had completed an 
assessment. We did several sensitivity analyses for 
comparisons of EQ-5D scores, quality-adjusted survival 
outcomes, and costs using a missing-at-random 
assumption conditional on treatment group, risk group, 
and either survival status at each follow-up time or 
follow-up time in the study to death or censoring, and 
final survival status. For all other secondary outcomes, 
we restricted analysis to patients who completed each 
test.
The economic analysis estimated the costs and cost-
effectiveness of VAT-PP versus talc pleurodesis up to 
12 months after randomisation from a National Health 
Service (NHS) perspective. Resources were valued using 
NHS reference costs (Department of Health, 2011), unit 
costs of health and social care,18 published literature, and 
the Papworth Hospital finance department. Costs are 
expressed in 2011–12 pounds sterling, inflated when 
necessary.18 We converted the EQ-5D, valued using the 
UK social tariff,19 to quality-adjusted life-years (QALYs) 
using the area under the curve method.20
Descriptive analyses show mean total costs by 
treatment group and differences between treatment 
group by category of cost for the original procedure and 
follow-up. We used non-parametric bootstrapping to 
estimate differences in mean costs with 95% CIs and 
incremental cost-effectiveness ratios. We represented 
uncertainty in cost-effectiveness acceptability curves and 
Figure 1: Trial profile
VAT-PP=video-assisted thoracoscopic partial pleurectomy.
196 randomly assigned
98 assigned to talc pleurodesis
10 excluded for not having mesothelioma
1 adenocarcinoma of lung
9 benign
0 metastatic carcinoma from 
extrathoracic primary
0 unconfirmed malignancy at 
study endpoint
88 patients with mesothelioma assigned 
to talc pleurodesis
73 received talc pleurodesis
15 did not receive talc pleurodesis 
4 no effusion or fluid did not 
re-accumulate
1 withdrew consent
1 pneumothorax
4 trapped lung
1 loculated effusion
1 disease progression
1 pleural thickening or no effusion
1 previous talc pleurodesis out of the trial
1 previous VAT-PP out of trial
1 month follow-up 
72 assessed for secondary outcomes
15 missed appointment
1 withdrew consent before 1 month
3 month follow-up 
71 assessed for secondary outcomes 
8 missed appointment
2 withdrew consent before 3 months
7 died before 3 months
6 month follow-up 
56 assessed for secondary outcomes
11 missed appointment
3 withdrew consent before 6 months
18 died before 6 months
12 month follow-up 
37 assessed for secondary outcomes
9 missed appointment
6 withdrew consent before 12 months 
(includes 2 who died before 12 months)
36 died before 12 months
98 assigned to VAT-PP
11 excluded for not having mesothelioma
2 adenocarcinoma of lung
6 benign
2 metastatic carcinoma from 
extrathoracic primary
1 unconfirmed malignancy at 
study endpoint
87 patients with mesothelioma assigned 
to VAT-PP
78 received VAT-PP
9 did not receive VAT-PP
1 died pre-procedure
1 surgery unsuccessful due to 
tumour spread
2 withdrew consent
1 trapped lung
2 natural pleurodesis after previous 
VAT biopsy
1 unable to tolerate single lung ventilation 
and small pleural space
1 inoperable due to chest wall invasion
1 month follow-up 
72 assessed for secondary outcomes
10 missed appointment 
3 withdrew consent before 1 month
2 died before 1 month
3 month follow-up 
66 assessed for secondary outcomes
8 died before 3 months
5 withdrew consent before 3 months
8 appointment missed
6 month follow-up 
56 assessed for secondary outcomes 
9 missed appointment
5 withdrew consent before 6 months 
(includes 2 who died before 6 months) 
17 died before 6 months
12 month follow-up 
34 assessed for secondary outcomes
9 missed appointment
5 withdrew consent before 12 months 
(includes 3 who died before 12 months) 
39 died before 12 months
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incremental net benefits for VAT-PP versus talc 
pleurodesis. Deterministic sensitivity analysis explored 
high-risk and low-risk subgroups, complications judged 
to be related to interventions, and the second half of the 
trial only (any patients randomly assigned after June 1, 
2009) to account for changing clinical practice over time. 
We finalised these subgroup analyses after trial 
completion, and they were exploratory.
This study is registered with an International Standard 
Randomised Controlled Trial Number, 34321019; the 
European Clinical Trials Database (EudraCT), number 
2011–001121–24; and with ClinicalTrials.gov, number 
NCT00821860
Role of the funding source
The funder of the study had no role in study design, data 
collection, data interpretation, or writing of the report. 
All authors had full access to all the data in the study and 
had final responsibility for the decision to submit for 
publication.
Results
As planned, we recruited 196 patients between Oct 24, 
2003, and Jan 24, 2012 (figure 1), and followed them up 
until Jan 31, 2013, with a further survival update on June 
17, 2013. At randomisation, 120 (61%) of 196 patients had 
confirmed malignant pleural mesothelioma and 76 (39%) 
had suspected (working diagnosis) malignant pleural 
mesothelioma (appendix). 11 (11%) of 98 patients 
assigned to VAT-PP and 10 (10%) of 98 patients assigned 
to talc pleurodesis with suspected malignant pleural 
mesothelioma were subsequently found to have benign 
disease (n=15), adenocarcinoma of the lung (n=3), 
metastatic disease from an extrathoracic primary cancer 
(n=2), or unconfirmed malignant pleural mesothelioma 
at study endpoint (n=1), and were excluded (figure 1). We 
analysed the remaining 87 patients in the VAT-PP group 
and 88 patients in the talc pleurodesis group in the 
intention-to-treat analyses.
Within 12 months of randomisation, 42 (48%) of 
87 patients in the VAT-PP group had died compared 
with 38 (43%) of 88 in the talc pleurodesis group; 
14 (16%) patients in the VAT-PP group and 15 (17%) in 
the talc pleurodesis group either withdrew from the 
study or did not attend the final appointment (figure 1). 
Thus, at 12 months secondary outcomes were available 
for 34 (39%) of 87 patients in the VAT-PP group and 
37 (42%) of 88 patients in the talc pleurodesis group, 
although some secondary outcomes were available for 
72 (83%) of 87 patients in the VAT-PP group and 
72 (82%) of 88 patients in the talc pleurodesis group. 
One patient withdrew following an MHRA decision, 
during the trial, to reclassify talc as a medicinal product, 
and the trial was suspended until MHRA registration. 
Other reasons for withdrawal from the trial are given in 
the appendix.
Baseline characteristics were similar between the two 
groups (table 1). Mean age was 69 years (SD 7·4) in all 
175 randomly assigned patients with mesothelioma, and 
151 (86%) were men. Most patients had epithelioid 
VAT-PP (n=87) Talc pleurodesis (n=88)
Age, years 69·5 (7·5) 69·4 (7·3)
Sex
Men 75 (86%) 76 (86%)
Women 12 (14%) 12 (14%)
EORTC risk status
High 38 (44%) 47 (53%)
Low 49 (56%) 41 (47%)
FEV1, L* 1·60 (0·62) 1·67 (0·56)
FEV1, % predicted* 57·0 (18·2) 59·3 (17·6)
FVC, L† 2·21 (0·82) 2·35 (0·75)
FVC, % predicted† 60·8 (17·8) 64·2 (18·3)
BMI, kg/m2‡ 26·6 (3·9) 27·2 (4·4)
Shuttle walk test, m§ 405·7 (154·3) 397·6 (163·3)
Tumour type
Epithelioid 73 (84%) 73 (83%)
Sarcomatoid 10 (11%) 7 (8%)
Biphasic 4 (5%) 8 (9%)
IMIG tumour stage
IA 2 (3%) 1 (1%)
IB 10 (13%) 7 (9%)
II 6 (8%) 9 (11%)
III 38 (49%) 34 (43%)
IV 21 (27%) 28 (35%)
Missing 10 (11%) 9 (10%)
ECOG performance status
0 20 (24%) 16 (19%)
1 50 (60%) 53 (62%)
2 11 (13%) 14 (16%)
3 3 (4%) 2 (2%)
Missing 3 (3%) 3 (3%)
Smoking
Current smoker 5 (6%) 4 (5%)
Ex-smoker 52 (61%) 45 (52%)
Never smoked 28 (33%) 38 (44%)
Missing 2 (2%) 1 (1%)
Asbestos exposure
Yes 64 (74%) 66 (76%)
No 4 (5%) 1 (1%)
Not known 18 (21%) 20 (23%)
Missing 1 (1%) 1 (1%)
Dyspnoea
Yes 67 (78%) 68 (78%)
No 19 (22%) 19 (22%)
Missing 1 (1%) 1 (1%)
Data are mean (SD) or number (%). VAT-PP=video-assisted thoracoscopic partial pleurectomy. EORTC=European 
Organisation for Research and Treatment of Cancer. FEV1=forced expiratory volume in 1 s. FVC=forced vital capacity. 
BMI=body-mass index. IMIG=International Mesothelioma Interest Group. ECOG=Eastern Cooperative Oncology Group. 
*n=76 in talc pleurodesis group; n=79 in VAT-PP group. †n=75 in talc pleurodesis group; n=79 in VAT-PP group. ‡n=74 
in talc pleurodesis group; n=74 in VAT-PP group. §n=49 in talc pleurodesis group; n=53 in VAT-PP group.
Table 1: Baseline demographic and clinical characteristics in randomly assigned patients with mesothelioma
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tumours (table 1). Three patients had a history of cancer 
(one had breast cancer and another had bladder cancer in 
the VAT-PP group, and one had prostate cancer in the 
talc pleurodesis group). ECOG performance status was 
0 or 1 for 139 (82%) of the 169 patients for whom data 
were available, and IMIG tumour stage was IA in 
three (2%) of 156 patients with available data, IB in 
17 (11%) patients, II in 15 (10%) patients, III in 
72 (46%) patients, and IV in 49 (31%) patients. Exposure 
to asbestos was reported by 130 (75%) of 173 patients with 
available data, and breathlessness was reported by 
135 (78%) of 173, with a percent-predicted mean forced 
expiratory volume in 1 s (FEV1) of 58·1% (SD 17·8).
Nine (10%) of 87 patients in the VAT-PP group did not 
undergo their assigned procedure, compared with 
15 (17%) of 88 patients in the talc pleurodesis group 
(figure 1). Talc pleurodesis commenced a median of 
9 days (IQR 6–15) after randomisation in 73 patients, 
with 35 (48%) receiving talc slurry and 34 (47%) 
undergoing pleurodesis via thoracoscopy (data for the 
remaining four patients are unavailable). VAT-PP was 
completed a median of 14 days (IQR 8–21) after 
randomisation.
Overall survival at 6 months was estimated to be 78% 
(95% CI 68–85) in the VAT-PP group and 80% (70–87) in 
the talc pleurodesis group, and at 1 year was estimated to 
be 52% (41–62) and 57% (46–66), respectively (hazard 
ratio [HR] 1·04 [95% CI 0·76–1·42]; p=0·81; figure 2A). 
Median overall survival was 13·1 months (IQR 7·3–20·3) 
in the VAT-PP group and 13·5 months (7·3–21·1) in the 
talc pleurodesis group. Overall survival at 6 months was 
estimated to be 66% (95% CI 48–78) in patients in the 
VAT-PP group who were at high risk according to the 
EORTC prognostic score and 74% (59–85) in patients in 
the talc pleurodesis group who were at high risk; for 
patients who were at low risk, overall survival at 6 months 
was 88% (75–94) and 85% (70–93), respectively 
(figure 2B). At 1 year, overall survival was 37% (95% CI 
22–52) in high-risk patients in the VAT-PP group and 
53% (38–66) in high-risk patients in the talc pleurodesis 
group, and 63% (48–75) and 61% (44–74) in the low-risk 
group for VAT-PP and talc pleurodesis, respectively 
(figure 2B). Overall survival rates were not significantly 
different between the treatment groups (stratified log-
rank test p=0·51). The HR of death for the VAT-PP group 
relative to the talc pleurodesis group, stratified by EORTC 
prognostic risk, was 1·11 (95% CI 0·81–1·53; p=0·51).
Pleural effusion was reported as apparently having 
resolved in 25 (37%) of 68 surviving patients in the talc 
pleurodesis group at 1 month, in 37 (60%) of 62 at 
3 months, in 31 (57%) of 54 at 6 months, and in 27 (77%) 
of 35 at 12 months. Corresponding numbers in the VAT-
PP group were 41 (59%) of 69 patients at 1 month, 
36 (60%) of 60 at 3 months, 41 (77%) of 53 at 6 months, 
and 23 (70%) of 33 at 12 months. The proportion of 
patients with resolved pleural effusion was significantly 
higher in the VAT-PP group than in the talc pleurodesis 
group at 1 month (p=0·008X) and 6 months (p=0·03X), 
but not at 3 months (p=0·97) or 12 months (p=0·49).
Of the 175 randomly assigned patients with malignant 
pleural mesothelioma, four patients withdrew within 
1 month, of whom two did not provide baseline data and 
two did; a further two patients did not complete baseline 
quality-of-life questionnaires, and three had one or more 
missing baseline EQ-5D items, leaving 83 patients in the 
VAT-PP group and 85 patients in the talc pleurodesis 
group with baseline EQ-5D data. The pattern of missing 
data during follow-up, which was more frequent just 
before death, is shown in the appendix. EQ-5D results are 
shown in figure 3 and the appendix. Patients in the VAT-
PP group had slightly worse EQ-5D utility index scores at 
1 month than patients in the talc pleurodesis group (mean 
difference −0·06 [95% CI −0·13 to 0·004]; p=0·07X), 
slightly better EQ-5D scores at 3 months (mean difference 
Figure 2: Kaplan-Meier curves of overall survival, in all patients and by risk group
Overall survival in all randomly assigned patients with mesothelioma, per treatment group (A) and in high-risk and 
low-risk patients, per treatment group (B). The vertical line crosses the x-axis at 1 year (primary endpoint). 
VAT-PP=video-assisted thoracoscopic partial pleurectomy.
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0·04 [−0·03 to 0·12]; p=0·27), and significantly better EQ-
5D scores at 6 months (mean difference 0·08 [0·003 to 
0·16]; p=0·042) and 12 months (mean difference 
0·19 [0·05 to 0·32]; p=0·006X). The mean number of 
QALYs in the VAT-PP group was 0·511 
(95% CI 0·446–0·577) compared with 0·476 (0·418–0·534) 
in the talc pleurodesis group (mean difference 0·035 
[−0·051 to 0·122]; p=0·42; table 2). Sensitivity analysis 
using a range of assumptions about missing data resulted 
in very similar estimates (appendix) and estimates of 
mean QALYs from all analyses were consistent.
Results of the analysis of some of the EORTC subscales 
(eg, global health, physical functioning, and role 
functioning) were similar to the results from the EQ-5D 
analysis (poorer function at 1 month and better function 
at 3, 6, and 12 months with VAT-PP than with talc 
pleurodesis), but results were not consistent between 
scales, nor were the differences noted between groups 
consistently significant (appendix).
Patients in the VAT-PP group had higher mean FEV1 at 1, 
3, and 12 months after treatment than did patients in the 
talc pleurodesis group, despite lower baseline function, 
but differences were not statistically significant (appendix). 
Forced vital capacity did not differ between groups 
(appendix). Patients in the talc pleurodesis group recorded 
a greater mean distance in the shuttle test, and the 
difference was significant at 12 months (difference 
103·5 m [95% CI 37·1–169·9]; p=0·003X), although this 
analysis was based on data from only 36 patients because 
the test was only done in five of the 12 participating centres.
We did not note any significant interactions between 
risk group and treatment group, but high-risk patients 
had significantly worse overall survival than low-risk 
patients (HR 1·64 [95% CI 1·19–2·25]; p=0·002X) and 
although some evidence suggested that high-risk patients 
who underwent VAT-PP had poorer overall survival than 
high-risk patients who underwent talc pleurodesis, the 
difference in overall survival between groups was not 
significant (HR 1·29 [95% CI 0·83–2·00]; p=0·25). The 
difference in mean EQ-5D score at 12 months in favour 
of patients with VAT-PP was significant for low-risk 
patients (mean difference 0·13 [95% CI 0·02–0·24]; 
p=0·022) and was large, but not significant, for high-risk 
patients (mean difference 0·32 [−0·04 to 0·67]; p=0·08X).
The mean cost of VAT-PP treatment and follow-up care 
for 12 months was about £3800 more than the cost of talc 
pleurodesis (appendix). Differences were mainly 
attributable to the initial procedure and increased length 
of stay, followed by the cost of admissions during follow-
up and treatment of surgical complications. The cost of 
gaining an additional QALY from VAT-PP is £109 000 
(table 3). A potential willingness-to-pay per QALY of 
£30 000 is associated with a 5·4% chance that VAT-PP 
was cost-effective relative to talc pleurodesis, and a 
willingness to pay per QALY of £50 000 is associated with 
a 20% chance (figure 4).
Deterministic sensitivity analysis (table 3) shows that 
high-risk patients in the VAT-PP group had fewer QALYs 
All patients High-risk group Low-risk group
Total cost
Talc pleurodesis 10 436 (14·4) 11 408 (19·0) 9359 (21·6)
VAT-PP 14 252 (14·4) 13 688 (19·1) 14 663 (21·7)
QALYs
Talc pleurodesis 0·476 (0·0005) 0·409 (0·0007) 0·555 (0·0007)
VAT-PP 0·511 (0·0006) 0·383 (0·0007) 0·607 (0·0009)
Difference in cost 3816 (20·7) 2274 (21·7) 5305 (19·1)
Difference in QALYs 0·035 (0·0008) –0·026 (0·00085) 0·050 (0·0007)
Incremental cost per QALY gained 109 028 VAT-PP dominated by TP* 105 119
Incremental net benefit at £30 000 per QALY −2766 −3054 −3805
Data are mean (SE) unless otherwise specified. Costs are presented in 2011 pound sterling (GBP£). This analysis uses bootstrapped estimates, not the imputed dataset (used 
in appendix). VAT-PP=video-assisted thoracoscopic partial pleurectomy. TP=talc pleurodesis. QALY=quality-adjusted life-year. *An intervention (ie, VAT-PP) is dominated 
when it is less effective and more costly than the comparator (ie, talc pleurodesis). 
Table 2: Comparison of costs and QALYs gained from VAT-PP versus talc pleurodesis
Figure 3: EQ-5D score during the 12 months after randomisation
Data are from patients who completed the ED-5D questionnaire at each 
timepoint (at baseline, 83 in VAT-PP group and 85 in talc pleurodesis group; 
1 month, n=71 and n=70; 3 months, n=63 and n=71; 6 months, n=55 and n=56; 
and 12 months, n=33 and n=36). Datapoints show mean ED-5D utility (index-
based value) and bars show 95% CI. VAT-PP=video-assisted thoracoscopic partial 
pleurectomy.
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and were more expensive to treat than were high-risk 
patients who received talc pleurodesis, whereas the low-
risk group had an additional cost of £105 119 per QALY 
gained for the VAT-PP group compared with the talc 
pleurodesis group. Using results from the second half of 
the trial only (after June 1, 2009; n=98), VAT-PP had a 
greater effect, with the incremental cost-effectiveness 
ratio falling to £68 600 per QALY gained (appendix).
Of the 78 patients who completed VAT-PP, respiratory 
complications were reported in 19 (24%) patients, 
cardiac complications in five (6%), and other (surgical) 
complications in 24 (31%). Of the 73 patients who 
completed talc pleurodesis, 11 (15%) had respiratory 
complications (p=0·22 for difference between treatment 
groups), three (4%) had cardiac complications (p=0·84), 
and ten (14%) had surgical complications (p=0·019). 
Some patients had more than one type of complication. 
Air leak beyond 2 days was significantly more common 
after VAT-PP than after talc pleurodesis, occurring in 
19 (24%) of 78 patients in the VAT-PP group versus 
four (5%) of 73 patients in the talc pleurodesis group 
(p=0·001X). Persistent air leak (>10 days) was more 
frequent in the VAT-PP group, but not significantly so 
(five [6%] vs one [1%]; p=0·21). 21 serious adverse events 
were related to the trial medication or procedure; 13 (in 
11 patients) were in the VAT-PP group and eight (in seven 
patients) were in the talc pleurodesis group (p=0·35; 
table 3). Full details of treatment complications are 
presented in the appendix. Median hospital stay after the 
procedure was 7 days (IQR 5–11) for the VAT-PP group 
and 3 days (IQR 2–5) for the talc pleurodesis group 
(p<0·0001). A similar proportion of patients in each 
group had chemotherapy after their study procedure 
(28 [32%] of 87 in the VAT-PP group vs 25 [28%] of 88 in 
the talc pleurodesis group), with a mean of 
4·4 cycles (SD 2·4) and 4·5 cycles (3·2), respectively.
Discussion
To our knowledge, our study is the first randomised 
controlled trial to compare VAT-PP and talc pleurodesis 
in patients with suspected or confirmed malignant 
pleural mesothelioma. Our results showed that overall 
survival was not improved by VAT-PP, and that this 
approach resulted in more complications, longer hospital 
stays, and was more expensive than was talc pleurodesis.
A study in a similar population of patients—the 
Mesothelioma and Radical Surgery (MARS) trial7—
compared extrapleural pneumonectomy (EPP) plus 
postoperative hemithoracic irradiation with no EPP in 
patients with mesothelioma who had received induction 
platinum-based chemotherapy. Although this feasibility 
study showed that recruitment and randomisation to 
EPP within the context of trimodality therapy was 
achievable, the adjusted HR in favour of not having EPP 
was 2·75 (95% CI 1·21–6·26; p=0·016). In view of the 
high morbidity associated with EPP, a larger study was 
not undertaken.
In recognition that many patients with mesothelioma 
present with advanced disease and comorbidities, 
MesoVATS assessed VAT-PP—a less arduous surgery 
than EPP. However, we found that this approach does 
not confer a survival advantage over talc pleurodesis and 
resulted in longer hospital stays. Median overall survival 
was 13·1 months in the VAT-PP group and 13·5 months 
and in the talc pleurodesis group (compared with 
14·4 months reported in the EPP group of MARS7) and 
was at the upper end of the range of 7–14 months reported 
in the systematic review of 14 observational studies and 
VAT-PP 
(n=78)
Talc pleurodesis 
(n=73)
Serious adverse events 13 (17%) 8 (11%)
Death 1  (1%) 0
Extended hospital stay
Renal failure 1 (1%) 0
Surgical emphysema 1 (1%) 0
Repeat VAT-PP and subsequent CVA 2 (3%) 0
Fever and dyspnoea 0 1 (1%)
Re-admissions
Leaking drain 3 (4%) 0
Persistent pleura effusion 1 (1%) 3 (4%)
Hydropneumothorax 1 (1%) 0
Empyema 1 (1%) 1 (1%)
Infected drain site 0 2 (3%)
Thoracotomy with decortication 0 1 (1%)
Symptom control 1 (1%) 0
Other
Awareness under anaesthesia 1 (1%) 0
Data are number of events (% of patients). VAT-PP=video-assisted thoracoscopic 
partial pleurectomy. CVA=cerebrovascular accident.
Table 3: Deaths and serious adverse events possibly or probably related 
to treatment
Figure 4: Cost-effectiveness and net monetary benefit of VAT-PP
QALY=quality-adjusted life-year. VAT-PP=video-assisted thoracoscopic partial pleurectomy.
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case series of partial pleurectomy.21 1-year overall survival 
in the VAT-PP group in our study (52%) was similar to 
our pre-trial estimate of 59%; however, our pre-trial 
estimate for the talc pleurodesis group of 37%, which 
was derived from audit data, was very different to the 
actual result (57%), and was probably based on less 
carefully selected patients than those put forward for 
VAT-PP. This result shows the bias inherent in many 
non-randomised comparisons.
So far, few studies into partial pleurectomy for 
malignant pleural mesothelioma have been published 
(panel). Since most patients with malignant pleural 
mesothelioma present with advanced disease, the 
findings from MesoVATS could be generalised, because 
78% of patients with a final diagnosis of malignant 
pleural mesothelioma were at IMIG stage III/IV and 
most had an ECOG performance status of 1. These 
results contrast with the more highly selected patients in 
the MARS trial who were predominantly IMIG stage II 
and had an ECOG performance status of 0 or 1.7 The 
advanced stage of disease at randomisation in our trial 
might explain why VAT-PP did not confer a survival 
advantage over talc pleurodesis; the more limited 
excision of tumour by VAT-PP than by EPP might have 
been insufficient to have an effect on overall survival. 
Future randomised studies examining lung-sparing 
(extended) pleurectomy with decortication at thoracotomy 
will establish whether more extensive resection provides 
a survival benefit with acceptable morbidity.
In the VAT-PP group, EQ-5D-assessed quality of life for 
surviving patients at 6 and 12 months was significantly 
better than that in the talc pleurodesis group. From a 
patient perspective, this finding is important because 
quality of life is a primary concern in the final months of 
life. Although the clinical significance of the observed 
improvements in EQ-5D is unclear since no pre-trial 
minimally important difference was posited, Pickard and 
colleagues22 suggest that a difference in EQ-5D utility in 
the range of 0·07–0·12 is important for patients with 
lung cancer. Differences of this order were achieved at 
6 and 12 months in the VAT-PP group compared with the 
talc pleurodesis group. However, the EQ-5D results were 
at odds with two cancer-specific quality-of-life question-
naires that did not show consistent improve ments in the 
VAT-PP group. Further studies examining the reasons 
for the variation in outcomes between the quality-of-life 
questionnaires in this scenario are required.
Historically, control of pleural effusion has been by talc 
pleurodesis, either using talc slurry via an intercostal 
drain, or by talc poudrage at thoracoscopy. During the 
study, practice shifted from administration of talc slurry 
via a chest drain towards increasing use of talc poudrage 
at thoracoscopy in line with contemporary practice 
(appendix). Previous studies of talc pleurodesis efficacy 
have shown effusion control rates (partial or complete) of 
between 60% and 84%, but these were in heterogeneous 
populations containing few patients with meso-
thelioma.23,24 Studies of talc pleurodesis efficacy focusing 
specifically on patients with mesothelioma seem to have 
lower success rates than studies in heterogeneous 
populations, probably because extensive visceral disease, 
common in mesothelioma, mitigates against successful 
pleurodesis because of failure of visceral and parietal 
pleura apposition combined with a paucity of normal 
mesothelial cells.25,26 A retrospective study27 of 165 patients 
with malignant pleural mesothelioma who underwent 
pleurodesis reported that pleural effusion was not 
controlled in 31% of patients, with no difference between 
talc slurry and talc poudrage. At the inception of our trial, 
the predominant method for assessing pleural effusion 
was chest radiograph—a less sensitive method than 
ultrasound, which is now widely used. In some cases, 
pleural tumour or pleural reaction after pleurodesis or 
pleurectomy might have been mistaken for a small 
recurrent pleural effusion. This factor should be taken 
into account when interpreting the results relating to 
fluid control. Others have defined failure of pleurodesis 
Panel: Research in context
Systematic review
We searched Medline, Embase, Cumulative Index to Nursing and Allied Health Literature, 
and the Cochrane Library for articles comparing talc pleurodesis with video-assisted 
thoracoscopic partial pleurectomy (VAT-PP) in patients with mesothelioma, using the 
keywords “mesothelioma”, “pleurect*”, “thoracic surgery”, and “talc pleurod*”. We 
screened the relevance of studies by assessment of titles, keywords, abstracts, and full 
texts. We used a Critical Appraisal Skills Programme checklist to assess the quality of the 
evidence. We found a few published studies that were similar to our own; however, 
surgical approaches that aim to remove all macroscopically visible tumour (extrapleural 
pneumonectomy and extended pleurectomy decortication) are not directly comparable 
with techniques such as partial pleurectomy, in which the aim is to partially remove 
parietal or visceral pleura for diagnostic or palliative purposes.6 Second, high-level 
evidence for partial pleurectomy is scarce in this setting. No randomised trials involving 
partial pleurectomy have been reported. Cao and colleagues21 reported a systematic 
review of safety and efficacy of pleurectomy (extended pleurectomy with decortication 
and partial pleurectomy) in patients with malignant pleural mesothelioma. Of 14 studies 
identified as containing patients who had undergone partial pleurectomy (assigned 
retrospectively on the basis of International Mesothelioma Interest Group or International 
Association for the Study of Lung Cancer criteria), most were retrospective, none assessed 
quality of life, and data completeness was variable. Surgical approaches varied between 
thoracotomy and video-assisted thoracoscopic surgery. Since all studies were 
non-randomised case series involving selected patients, spanning a wide timeframe 
(1958–2008), with variable methods and reporting, we found it difficult to draw 
conclusions other than noting that median survival ranged from 7 to 14 months.
Interpretation
Our trial is the first, to our knowledge, to compare VAT-PP and talc pleurodesis in a 
randomised controlled trial. With regard to future clinical practice, our results show that 
VAT-PP does not offer a survival advantage over talc pleurodesis and is associated with 
more surgical complications.  However, we found some evidence that low-risk patients 
who are expected to survive at least 6 months might benefit in terms of quality of life 
from VAT-PP. Future randomised studies of lung sparing (extended) pleurectomy with 
decortication at thoracotomy should examine whether more extensive pleural resection 
confers benefit in terms of survival and quality-of-life measures.
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as the need for further pleural intervention for fluid 
control.28 Data for subsequent pleural interventions were 
not routinely obtained in our study.
In the economic analysis, VAT-PP cost an additional 
£3800 per patient compared with talc pleurodesis. The 
additional 0·035 QALYs gained per patient (equivalent to 
12·5 days of full health) could be bought at a rate of 
£109 000 per QALY. Due to the prolonged recruitment 
period and changes in management over time, we 
estimated cost-effectiveness in only patients recruited in 
the second half of the trial (98 patients randomised after 
June 1, 2009). For this group, the cost per QALY was 
£68 600, which is closer to, but in excess of, the highest 
cost per QALY of a drug (£50 000) accepted by NICE in 
previous decisions for end-of-life treatments.29 The 
reason for the improvement in cost-effectiveness is 
multifactorial. After study midpoint, trial patients 
undergoing VAT-PP had a slightly lower median hospital 
stay than did earlier patients (7 days [IQR 5–7] vs 8 days 
[6–11]) whereas patients with talc pleurodesis had a very 
similar but slightly higher median hospital stay than did 
earlier patients (4 days [2–7] vs 3 days [2–5]), resulting 
from greater use of thoracoscopy and talc poudrage in 
the second half of the trial (appendix), which is more 
expensive (talc pleurodesis cost £1129 in the first half of 
the trial and £2649 in the second half). Additionally, we 
noted some evidence of a greater difference between the 
groups in EQ-5D score at 6 and 12 months in the second 
half of the trial, whereas survival remained similar for 
the two groups (appendix).
Since VAT-PP was both more expensive and less 
effective than talc pleurodesis in the high-risk subgroup, 
there seems to be little rationale for this procedure in 
these patients. However, treatment of low-risk patients 
with VAT-PP might have some economic justification if 
the end-of-life willingness-to-pay threshold is raised to 
£68 600 per QALY or if future studies show that the costs 
of VAT-PP relative to talc pleurodesis continue to decline 
further. Further refinement of risk classification systems 
might also help to identify patients who might benefit 
most from each treatment.
During the 10 years of study recruitment, several 
changes in the clinical management of malignant pleural 
mesothelioma occurred. With regard to staging, 
MesoVATS used CT, although recent research has shown 
that although CT remains the first-line investigation 
method, PET-CT, and in certain circumstances, MRI, 
might improve the accuracy of staging.30,31 NICE guidance 
(2008)29 on cisplatin plus pemetrexed chemotherapy for 
mesothelioma resulted in more patients in the second 
half of the study receiving chemotherapy after study 
treatment. Because similar numbers of patients in each 
group had post-procedure chemotherapy, we felt the use 
of chemotherapy in the clinical management of the 
disease did not unduly bias the results.
The poor prognosis and high morbidity in this group of 
patients meant that secondary outcomes were available 
for less than half the population by 12 months, although 
results were robust to a range of missing data analyses. 
Because the study was open label with group allocations 
available to patients, clinicians, and researchers, we 
cannot exclude bias in secondary outcomes as a result of 
a patient or clinician having a strong preference for one 
of the treatments.
In conclusion, VAT-PP had no effect on overall survival, 
resulted in more complications, longer hospital stay, and 
was more expensive than talc pleurodesis in patients 
with pleural effusion due to malignant pleural 
mesothelioma. However, significant improvement in 
EQ-5D score at 6 and 12 months in the VAT-PP group 
suggests that this treatment might have a role in patients 
expected to survive at least 6 months. Subgroup analysis 
suggests that patients in the EORTC low-risk prognostic 
group might benefit most from VAT-PP, and further 
work in this subgroup might be appropriate.
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